全文获取类型
收费全文 | 81920篇 |
免费 | 6387篇 |
国内免费 | 259篇 |
专业分类
耳鼻咽喉 | 934篇 |
儿科学 | 2184篇 |
妇产科学 | 1135篇 |
基础医学 | 11252篇 |
口腔科学 | 871篇 |
临床医学 | 8690篇 |
内科学 | 17514篇 |
皮肤病学 | 929篇 |
神经病学 | 8007篇 |
特种医学 | 3198篇 |
外科学 | 13144篇 |
综合类 | 925篇 |
一般理论 | 91篇 |
预防医学 | 6153篇 |
眼科学 | 2045篇 |
药学 | 5639篇 |
中国医学 | 96篇 |
肿瘤学 | 5759篇 |
出版年
2023年 | 616篇 |
2022年 | 901篇 |
2021年 | 2456篇 |
2020年 | 1384篇 |
2019年 | 2244篇 |
2018年 | 2568篇 |
2017年 | 1836篇 |
2016年 | 1921篇 |
2015年 | 2268篇 |
2014年 | 3262篇 |
2013年 | 4170篇 |
2012年 | 6625篇 |
2011年 | 6877篇 |
2010年 | 3767篇 |
2009年 | 3299篇 |
2008年 | 5544篇 |
2007年 | 5727篇 |
2006年 | 5297篇 |
2005年 | 5251篇 |
2004年 | 4754篇 |
2003年 | 4349篇 |
2002年 | 3948篇 |
2001年 | 700篇 |
2000年 | 504篇 |
1999年 | 674篇 |
1998年 | 835篇 |
1997年 | 620篇 |
1996年 | 508篇 |
1995年 | 456篇 |
1994年 | 442篇 |
1993年 | 433篇 |
1992年 | 333篇 |
1991年 | 269篇 |
1990年 | 250篇 |
1989年 | 228篇 |
1988年 | 212篇 |
1987年 | 191篇 |
1986年 | 177篇 |
1985年 | 194篇 |
1984年 | 222篇 |
1983年 | 182篇 |
1982年 | 264篇 |
1981年 | 250篇 |
1980年 | 185篇 |
1979年 | 124篇 |
1978年 | 132篇 |
1977年 | 115篇 |
1976年 | 79篇 |
1975年 | 79篇 |
1972年 | 72篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
4.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
5.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献6.
7.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献8.
9.
10.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献